When would you consider neoadjuvant immunotherapy for advanced melanoma?  

For example, would you consider this in a patient that would otherwise be eligible for adjuvant treatment (stage III or stage IV with oligometastatic disease)? Would you consider doing so based on limited data from Safety, activity, and biomarkers for neoadjuvant anti-PD-1 therapy in melanoma and/or extrapolating from recent NSCLC data?

 



Answer from: Medical Oncologist at Academic Institution